This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data

The acromegaly disease activity tool designed to help monitor your patients

Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data

Learn about funding and reimbursement England, Scotland, Wales and Northern Ireland

Watch and listen to acromegaly experts talk about various topics in the disease area as well as recordings from our National Nurse Meeting and the Acromegaly co-morbidity series

Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.

Efficacy

Somavert normalises IGF-1 in a unique way1

Somavert mechanism of action

Somavert works on cell surfaces around the body, directly targeting and blocking growth hormone receptors to inhibit IGF-I production with a high predictibility1-3

Somavert can help achieve high rates of IGF-I normalisation1,3

Somavert IGF-I normalisation rates at 12 weeks and 12 months

Somavert’s tumour-independent mechanism of action may explain how it can achieve IGF-I normalisation notes of up to 97% when appropriately titrated (n=90, p<0.05)3

p=0.02 **p<0.001. Maximum recommended dose of Somavert should not exceed 30mg daily1 

Somavert seeks to minimise the impact of acromegaly on quality of life

Somavert symptom score reductions at 6 months

Patients on Somavert report significant reductions versus baseline in soft tissue swelling, headache, joint pain and general physical condition, and total signs and symptoms score‡1,5

Total signs and symptoms score reduction observed at 12 weeks (p<0.05, n=112).

Why target IGF-I?

Professor AJ van der Lely. Erasmus MC, Rotterdam, Netherlands, explains the vital role of IGF-I, the liver and insulin production in acromeagly and its treatment 

Discover more webinars

Track IGF-I, symptoms and co-morbidities with ACRODAT

Learn more

Explore more

Contact us

To find out more about ACRODAT, supporting your patients or to order starter kits 

Contact us

Somavert safety profile

Learn about the Somavert safety profile from clinical and real world data​​​​​​​

Learn more 

References 
​​​​​​​
1. Somavert Summary of Product Characteristics. Available here 
2. Sherlock M, et al. Medical therapy in acromegaly. Nat Rev Endocrinol 2011;7:291–300.
3. Van der Lely AJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;24;358(9295):1754–9.
4. Trainer PJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342(16):1171–7.
5. Schreiber I, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007;156:75–82.

PP-SOM-GBR-0952. June 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No